

# Jennifer L Sauter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/950955/publications.pdf>

Version: 2024-02-01

39  
papers

5,844  
citations

279701

23  
h-index

345118

36  
g-index

40  
all docs

40  
docs citations

40  
times ranked

8245  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Characterization of Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2022, 17, 455-460.	0.5	24
2	The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. <i>Journal of Thoracic Oncology</i> , 2022, 17, 608-622.	0.5	64
3	Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3797-3803.	3.2	15
4	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-“PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	7.7	222
5	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576.	5.9	23
6	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 5-12.	0.6	26
7	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 303-311.	2.9	65
8	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106
9	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247.	0.5	172
10	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835.	0.5	234
11	Results from the 2019 American Society of “Cytopathology survey on rapid onsite evaluation (ROSE)“ part 2: subjective views among the cytopathology community. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 570-578.	0.2	11
12	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708.	3.2	133
13	In Reply. <i>Journal of Thoracic Oncology</i> , 2020, 15, e94-e95.	0.5	0
14	Validation of a digital pathology system including remote review during the COVID-19 pandemic. <i>Modern Pathology</i> , 2020, 33, 2115-2127.	2.9	112
15	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1037-1053.	0.5	40
16	Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. <i>Histopathology</i> , 2020, 77, 915-925.	1.6	92
17	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
18	Assessment of The Bethesda System for Reporting Thyroid Cytopathology. <i>American Journal of Clinical Pathology</i> , 2019, 152, 502-511.	0.4	24

#	ARTICLE	IF	CITATIONS
19	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1989-1994.	0.5	10
20	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. <i>Clinical Cancer Research</i> , 2019, 25, 7113-7125.	3.2	69
21	Results from the 2019 American Society of Cytopathology survey on rapid on-site evaluation—Part 1: objective practice patterns. <i>Journal of the American Society of Cytopathology</i> , 2019, 8, 333-341.	0.2	30
22	Displaced Cartilage Within Lymph Node Parenchyma Is a Novel Biopsy Site Change in Resected Mediastinal Lymph Nodes Following EBUS-TBNA. <i>American Journal of Surgical Pathology</i> , 2019, 43, 497-503.	2.1	10
23	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.4	226
24	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
25	Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. <i>Modern Pathology</i> , 2018, 31, 598-606.	2.9	70
26	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
27	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
28	Bronchiolar Adenoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1010-1026.	2.1	91
29	Type A thymoma presenting with bone metastasis. <i>Histopathology</i> , 2018, 73, 701-703.	1.6	1
30	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	0.5	589
31	SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. <i>Modern Pathology</i> , 2017, 30, 1422-1432.	2.9	135
32	Young investigator challenge: Validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens. <i>Cancer Cytopathology</i> , 2016, 124, 89-100.	1.4	63
33	Increased utilization, verification, and clinical implications of immunocytochemistry: Experience in a northern New England hospital. <i>Diagnostic Cytopathology</i> , 2015, 43, 688-695.	0.5	9
34	Pathological findings in spontaneous pneumothorax specimens: does the incidence of unexpected clinically significant findings justify routine histological examination?. <i>Histopathology</i> , 2015, 66, 675-684.	1.6	6
35	Have the 2006 American Society for Colposcopy and Cervical Pathology (ASCCP) Guidelines Enriched the Yield of High-Grade Squamous Intraepithelial lesions?. <i>Diagnostic Cytopathology</i> , 2015, 43, 673-675.	0.5	0
36	Testing of Integrated Human Papillomavirus mRNA Decreases Colposcopy Referrals: Could a Change in Human Papillomavirus Detection Methodology Lead to More Cost-Effective Patient Care?. <i>Acta Cytologica</i> , 2014, 58, 162-166.	0.7	18

#	ARTICLE	IF	CITATIONS
37	Expanding the spectrum of pulmonary histopathological manifestations of anti- <i>CCP</i> syndrome: anti- <i>CCP</i> -associated acute fibrinous and organizing pneumonia. <i>Histopathology</i> , 2014, 65, 581-582.	1.6	24
38	Co-existence of <i>Sarcina</i> Organisms and <i>Helicobacter pylori</i> Gastritis/Duodenitis in Pediatric Siblings. <i>Journal of Clinical &amp; Anatomic Pathology (JCAP)</i> , 2013, 1, .	0.4	8
39	Immune checkpoint inhibitor-related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease. <i>Histopathology</i> , 0, , .	1.6	4